Cita APA

M, M., C, Z., M, R., E, C., EM, C., M, M., . . . M, G. (2022). Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.

Citación estilo Chicago

M, Martín, et al. Overall Survival With Palbociclib Plus Endocrine Therapy Versus Capecitabine in Postmenopausal Patients With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer in the PEARL Study. 2022.

Cita MLA

M, Martín, et al. Overall Survival With Palbociclib Plus Endocrine Therapy Versus Capecitabine in Postmenopausal Patients With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer in the PEARL Study. 2022.